AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 741.38 |
Market Cap | 705.36B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | 9.25 |
PE Ratio (ttm) | 80.33 |
Forward PE | n/a |
Analyst | Buy |
Ask | 751 |
Volume | 9,444,635 |
Avg. Volume (20D) | 3,891,521 |
Open | 784.23 |
Previous Close | 797.48 |
Day's Range | 729.00 - 784.23 |
52-Week Range | 612.70 - 972.53 |
Beta | undefined |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...
Analyst Forecast
According to 27 analyst ratings, the average rating for LLY stock is "Buy." The 12-month stock price forecast is $1008, which is an increase of 35.66% from the latest price.
Next Earnings Release
Analysts project revenue of $13.95B, reflecting a 49.15% YoY growth and earnings per share of 5.42, making a 117.67% increase YoY.
18 hours ago · investopedia.com
S&P 500 Gains and Losses Today: Eli Lilly Stock Falls as Sales Outlook WeakensMajor U.S. equities indexes were mixed on Tuesday after the latest Producer Price Index (PPI) data showed a lighter-than-expected uptick in wholesale prices for December. The soft PPI report helped al...
21 hours ago · proactiveinvestors.com
Eli Lilly stumbles as weight-loss drug sales less than expectedShares in Eli Lilly and Co fell 6.4% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US market for ...
22 hours ago · proactiveinvestors.com
Eli Lilly lowers FY revenue forecast as weight loss drug sales fall shortShares in Eli Lilly and Co (NYSE:LLY) fell 7.3% after the drugmaker said sales of its Mounjaro and Zepbound weight-loss medications grew more slowly than it had expected. CEO David Ricks said the US m...
1 day ago · youtube.com
Cramer's Mad Dash: Eli LillyCNBC's Jim Cramer delivers his daily Mad Dash.